Handa’s Omcazio hybrid drug has won final US approval after Exelixis dropped its patent suit and failed to persuade the FDA to block the 505(b)(2) product, opening another route into the blockbuster ...

Humana is seeking to lift a 45-day stay on its generic price-fixing bellwether against Mylan and Lannett, as the parties clash over whether special discovery master Lawrence Stengel should remain ...